SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 13, 2015
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction
650 East Kendall Street
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants telephone number, including area code: (617) 299-5000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 8.01||Other Events.|
On March 13, 2015, Aveo Pharmaceuticals, Inc. (the Company) received notification from the Listing Qualifications Department (the Staff) of The NASDAQ Stock Market notifying the Company it had regained compliance with NASDAQ Listing Rule 5450(a)(1) (the Rule), which requires a minimum $1.00 per share bid price for the Companys common stock. The Company had previously reported its receipt of a deficiency letter from the Staff notifying the Company that the bid price for the Companys common stock had closed for a period of 30 consecutive days below the minimum $1.00 per share requirement for continued inclusion on The NASDAQ Global Market pursuant to the Rule.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|AVEO Pharmaceuticals, Inc.|
|Date: March 19, 2015|
/s/ Michael Bailey
|President and Chief Executive Officer|